Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LOWELL R SCHMELTZ

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1538112917
CMS profile
342238
Location
FARMINGTON HILLS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$268,937.00

520 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 11 of 11; records 501–520 of 520 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LOWELL R SCHMELTZ

NPI 1538112917 · CMS profile ID 342238

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

FARMINGTON HILLS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 11 of 11; records 501–520 of 520 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538112917?year=2019&recipient=provider&page=11#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LOWELL R SCHMELTZ, NPI 1538112917, CMS profile ID 342238. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 11 of 11; records 501–520 of 520 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538112917?year=2019&recipient=provider&page=11#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). LOWELL R SCHMELTZ, NPI 1538112917, CMS profile ID 342238. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 11 of 11; records 501–520 of 520 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538112917?year=2019&recipient=provider&page=11#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
LOWELL R SCHMELTZ, NPI 1538112917, CMS profile ID 342238, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 11 of 11; records 501–520 of 520 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1538112917?year=2019&recipient=provider&page=11#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

520 matching records · $268,937.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 520 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 501–520 of 520.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $12.0702/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659269799 CMS
Lilly USA, LLC $89.2602/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657979809 CMS
Amgen Inc. $12.6002/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662659515 CMS
Lilly USA, LLC $3,600.0002/04/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657969843 CMS
Lilly USA, LLC $800.0002/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657976565 CMS
PFIZER INC. $14.1301/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671858953 CMS
Merck Sharp & Dohme Corporation $8.7001/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695258059 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $509.1101/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700211667 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $229.3701/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700211669 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $59.8101/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700211671 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $46.0101/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700211673 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $144.0201/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700211685 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $31.1201/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700211707 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.8601/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684927467 CMS
Novo Nordisk Inc $13.6601/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 668790931 CMS
Novo Nordisk Inc $2.8901/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682901401 CMS
AbbVie, Inc. $23.2801/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648265771 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $2,200.0001/16/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700211677 CMS
SANOFI-AVENTIS U.S. LLC $14.5801/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693900191 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $2,200.0001/03/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700211703 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $268,937.00 520
PY2020 $154,313.13 271
PY2021 $200,202.93 308
PY2022 $159,058.24 307
PY2023 $135,689.98 323
PY2024 $156,352.61 302
PY2025 $226,925.80 351

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $529,485.58 74
PY2024 Principal investigator $168,265.51 25
PY2023 Principal investigator $122,312.46 35
PY2022 Principal investigator $136,784.76 58
PY2021 Principal investigator $10,306.27 28

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

74 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,520.00 12/31/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202532450
Principal investigator 1 ABBVIE INC. $2,275.00 12/30/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202532170
Principal investigator 1 ABBVIE INC. $2,700.00 12/11/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202530070
Principal investigator 1 ABBVIE INC. $24,108.41 12/05/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202529294
Principal investigator 1 ABBVIE INC. $500.00 12/04/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202527484
Principal investigator 1 ABBVIE INC. $2,652.24 12/04/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202527486
Principal investigator 1 ABBVIE INC. $1,950.00 12/03/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202526378
Principal investigator 1 ABBVIE INC. $1,359.28 12/01/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202526178
Principal investigator 1 ABBVIE INC. $1,432.08 11/06/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202523427
Principal investigator 1 ABBVIE INC. $500.00 11/06/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202523429
Principal investigator 1 ABBVIE INC. $500.00 11/04/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202520819
Principal investigator 1 SANOFI US SERVICES INC. $5,289.74 11/04/2025 Non-covered Recipient Entity
Profound Research Llc
A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2a Study Assessing Safety and Efficacy of SAR442970, a Dual Anti-TNF and Anti-OX40L NANOBODY Molecule, for Preservation of Pancreatic B-cell Function in Adults and Adolescents With Recently Diagnosed Type 1 Diabetes No dispute reported 06/30/2026 1226132242
Principal investigator 1 ABBVIE INC. $2,550.00 10/30/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202519715
Principal investigator 1 ABBVIE INC. $65,278.62 10/30/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202519869
Principal investigator 1 SANOFI US SERVICES INC. $150.00 10/20/2025 Non-covered Recipient Entity
Profound Research Llc
A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2a Study Assessing Safety and Efficacy of SAR442970, a Dual Anti-TNF and Anti-OX40L NANOBODY Molecule, for Preservation of Pancreatic B-cell Function in Adults and Adolescents With Recently Diagnosed Type 1 Diabetes No dispute reported 06/30/2026 1226132200
Principal investigator 1 SANOFI US SERVICES INC. $4,043.06 10/20/2025 Non-covered Recipient Entity
Profound Research Llc
A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2a Study Assessing Safety and Efficacy of SAR442970, a Dual Anti-TNF and Anti-OX40L NANOBODY Molecule, for Preservation of Pancreatic B-cell Function in Adults and Adolescents With Recently Diagnosed Type 1 Diabetes No dispute reported 06/30/2026 1226132204
Principal investigator 1 ABBVIE INC. $973.52 10/15/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202516875
Principal investigator 1 ABBVIE INC. $729.40 10/14/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202516645
Principal investigator 1 ABBVIE INC. $300.00 10/14/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202516647
Principal investigator 1 ABBVIE INC. $13,075.00 10/14/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202516729
Principal investigator 1 ABBVIE INC. $2,725.00 10/10/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202516577
Principal investigator 1 ABBVIE INC. $49,538.71 10/09/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202514361
Principal investigator 1 ABBVIE INC. $911.40 09/30/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202512884
Principal investigator 1 SANOFI US SERVICES INC. $4,253.14 09/29/2025 Non-covered Recipient Entity
Profound Research Llc
A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2a Study Assessing Safety and Efficacy of SAR442970, a Dual Anti-TNF and Anti-OX40L NANOBODY Molecule, for Preservation of Pancreatic B-cell Function in Adults and Adolescents With Recently Diagnosed Type 1 Diabetes No dispute reported 06/30/2026 1226132180
Principal investigator 1 SANOFI US SERVICES INC. $13,125.36 09/29/2025 Non-covered Recipient Entity
Profound Research Llc
A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2a Study Assessing Safety and Efficacy of SAR442970, a Dual Anti-TNF and Anti-OX40L NANOBODY Molecule, for Preservation of Pancreatic B-cell Function in Adults and Adolescents With Recently Diagnosed Type 1 Diabetes No dispute reported 06/30/2026 1226132184
Principal investigator 1 SANOFI US SERVICES INC. $500.00 09/29/2025 Non-covered Recipient Entity
Profound Research Llc
A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2a Study Assessing Safety and Efficacy of SAR442970, a Dual Anti-TNF and Anti-OX40L NANOBODY Molecule, for Preservation of Pancreatic B-cell Function in Adults and Adolescents With Recently Diagnosed Type 1 Diabetes No dispute reported 06/30/2026 1226132188
Principal investigator 1 ABBVIE INC. $1,622.60 09/23/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202511924
Principal investigator 1 ABBVIE INC. $1,079.28 09/11/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202510776
Principal investigator 1 ABBVIE INC. $488.60 09/11/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202510788
Principal investigator 1 ABBVIE INC. $43,615.48 09/04/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509896
Principal investigator 1 ABBVIE INC. $500.00 09/03/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202508296
Principal investigator 1 ABBVIE INC. $900.00 09/02/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202506995
Principal investigator 1 SANOFI US SERVICES INC. $143.00 08/25/2025 Non-covered Recipient Entity
Profound Research Llc
A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2a Study Assessing Safety and Efficacy of SAR442970, a Dual Anti-TNF and Anti-OX40L NANOBODY Molecule, for Preservation of Pancreatic B-cell Function in Adults and Adolescents With Recently Diagnosed Type 1 Diabetes No dispute reported 06/30/2026 1226132177
Principal investigator 1 ABBVIE INC. $655.20 08/21/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202505387
Principal investigator 1 ABBVIE INC. $1,500.00 08/21/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202505409
Principal investigator 1 ABBVIE INC. $42,324.35 08/06/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202502618
Principal investigator 1 ABBVIE INC. $502.60 08/05/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202501404
Principal investigator 1 ABBVIE INC. $471.80 07/16/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202498386
Principal investigator 1 SANOFI US SERVICES INC. $18,259.00 07/07/2025 Non-covered Recipient Entity
Profound Research Llc
A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2a Study Assessing Safety and Efficacy of SAR442970, a Dual Anti-TNF and Anti-OX40L NANOBODY Molecule, for Preservation of Pancreatic B-cell Function in Adults and Adolescents With Recently Diagnosed Type 1 Diabetes No dispute reported 06/30/2026 1226132038
Principal investigator 1 ABBVIE INC. $338.80 07/02/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202495187
Principal investigator 1 ABBVIE INC. $500.00 07/02/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202495205
Principal investigator 1 ABBVIE INC. $280.00 07/02/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202495207
Principal investigator 1 ABBVIE INC. $48,568.66 07/02/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202495209
Principal investigator 1 ABBVIE INC. $488.60 06/17/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202491889
Principal investigator 1 ABBVIE INC. $553.00 06/10/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202490711
Principal investigator 1 ABBVIE INC. $42,870.10 06/03/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202488083
Principal investigator 1 ABBVIE INC. $154.00 05/30/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202487123
Principal investigator 1 ABBVIE INC. $4,440.00 05/30/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202487125
Principal investigator 1 ABBVIE INC. $1,400.00 05/15/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202485029
Principal investigator 1 ABBVIE INC. $1,400.00 05/15/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202485039
Principal investigator 1 ABBVIE INC. $3,492.89 05/13/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202484719
Principal investigator 1 ABBVIE INC. $23,000.97 05/07/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202482933
Principal investigator 1 ABBVIE INC. $170.80 05/06/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202481561
Principal investigator 1 ABBVIE INC. $68.60 05/06/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202481615
Principal investigator 1 ABBVIE INC. $137.20 05/01/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202480763
Principal investigator 1 ABBVIE INC. $730.80 04/28/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202479753
Principal investigator 1 ABBVIE INC. $270.20 04/28/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202479769
Principal investigator 1 ABBVIE INC. $206.44 04/28/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202479774
Principal investigator 1 ABBVIE INC. $68.60 04/15/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202476543
Principal investigator 1 ABBVIE INC. $24,388.02 04/03/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202469051
Principal investigator 1 ABBVIE INC. $420.00 04/01/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202467756
Principal investigator 1 ABBVIE INC. $500.00 03/27/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202466941
Principal investigator 1 ABBVIE INC. $99.40 03/19/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202464376
Principal investigator 1 ABBVIE INC. $68.60 03/18/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202464213
Principal investigator 1 Siemens Medical Solutions USA, Inc. $21,533.00 03/14/2025 Non-covered Recipient Entity
MICHIGAN HEALTHCARE, PROFESSIONALS PC
Specimen Collection for Siemens Thyroid Antibody Assays No dispute reported 06/30/2026 1173556670
Principal investigator 1 ABBVIE INC. $20,162.70 03/07/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202461682
Principal investigator 1 ABBVIE INC. $140.00 03/04/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202455704
Principal investigator 1 ABBVIE INC. $140.00 02/12/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202450680
Principal investigator 1 ABBVIE INC. $628.60 02/12/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202450812
Principal investigator 1 ABBVIE INC. $7,425.59 02/06/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202448014
Principal investigator 1 ABBVIE INC. $518.60 02/04/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202443868
Principal investigator 1 ABBVIE INC. $68.60 01/13/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202438112
Principal investigator 1 ABBVIE INC. $500.00 01/07/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202436969
Principal investigator 1 ABBVIE INC. $4,750.94 01/02/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202434477